Telormedix raises $6.6m from Aravis and Proquest

The investment is an extension of the firm's series-B financing round, which saw Telormedix raising €6.16m from Aravis Venture and Proquest Investments in early 2012.

Aravis has been backing Telormedix since 2008, when the VC led a €13.1m series-A round alongside Proquest Investments, BSI, Nextech Venture and Generali Insurance Group.

Company
Bioggio-based Telormedix develops pharmaceuticals for the treatment of cancer and autoimmune diseases. Telormedix's lead product is TMX-101, which recently entered phase-I and phase-II clinical trials for the treatment of non-muscle invasive bladder cancer. The open-label phase-II clinical trial involves 12 patients suffering from clinically isolated syndrome in private urology clinics in the US, which will examine the efficacy of the drug over six doses.

People
Johanna Holldack is the CEO of Telormedix. Alain Schreiber is general partner at ProQuest Investments. Jean-Philippe Tripet is managing partner and founder of Aravis.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland